Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | ASP2074 |
Synonyms | |
Therapy Description |
ASP2074 is a bispecific antibody targeting TSPAN8 on tumor cells and CD3 on T-cells, which potentially induces antitumor activity (Mol Cancer Ther (2023) 22 (12_Supplement): A173). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
ASP2074 | ASP-2074|ASP 2074 | CD3 Antibody 99 | ASP2074 is a bispecific antibody targeting TSPAN8 on tumor cells and CD3 on T-cells, which potentially induces antitumor activity (Mol Cancer Ther (2023) 22 (12_Supplement): A173). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05646797 | Phase I | ASP2074 | A Study of ASP2074 in Adults With Solid Tumors | Terminated | USA | 1 |